Human Paraoxonase 1 (PON1) Protein

Product Graph
234€ (10 µg)

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.

935106861
info@markelab.com
name
Human Paraoxonase 1 (PON1) Protein
category
Proteins and Peptides
provider
Abbexa
reference
abx068421
tested applications
WB, SDS-PAGE

Description

Human Paraoxonase 1 (PON1) is a recombinant Human protein expressed in E. coli.

Documents del producto

Instrucciones
Data sheet
Descargar

Product specifications

Category
Proteins and Peptides
Immunogen Target
Paraoxonase 1 (PON1)
Host
E. coli
Assay Type
Activity: Not tested
Sequence Fragment: Gln35-Val206
Tag: N-terminal His tag
Origin
Human
Conjugation
Unconjugated
Observed MW
Calculated MW: 20.8 kDa  Observed MW (SDS-PAGE): 21 kDa
Expression
Recombinant
Purity
> 97%
Size 1
10 µg
Size 2
50 µg
Size 3
100 µg
Size 4
200 µg
Size 5
500 µg
Form
Lyophilized
Tested Applications
WB, SDS-PAGE
Buffer
Prior to lyophilization: 20 mM Tris, 150 mM NaCl, pH 8.0, containing 0.01% Sarcosyl, 5% Trehalose.
Availability
Shipped within 5-7 working days.
Storage
Store lyophilized form at 2-8°C for up to 1 month. For longer periods, store lyophilized or liquid at -80°C. Avoid repeated freeze–thaw cycles.
Dry Ice
No
UniProt ID
P27169
Gene ID
5444
Background
Protein PON1
Status
RUO
Note
THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION.
Reconstitute in ddH2O to a concentration between 0.1-1.0 mg/ml. Do not vortex.
Concentration: Prior to lyophilization: 100 µg/ml

Descripción

Related Products

EH0257

Human PON1 (Serum paraoxonase/arylesterase 1) ELISA Kit

Ver Producto
ER0265

Rat Pon1 (Serum paraoxonase/arylesterase 1) ELISA Kit

Ver Producto
FNab06638

PON1 antibody

Hydrolyzes the toxic metabolites of a variety of organophosphorus insecticides. Capable of hydrolyzing a broad spectrum of organophosphate substrates and lactones, and a number of aromatic carboxylic acid esters. Mediates an enzymatic protection of low density lipoproteins against oxidative modification and the consequent series of events leading to atheroma formation.

Ver Producto